Myriad Discovers New Genes, Receives More Patents on BRCA1 | GenomeWeb

SALT LAKE CITY--Myriad Genetics here has announced three new gene discoveries and gained two more patents on the BRCA1 gene. In addition, the company is suing OncorMed for patent infringement relating to one of the new patents.

The gene discoveries could open the door for developing new cancer treatments, according to Myriad. They were made using the company's ProNet protein interaction technology that rapidly identifies proteins with potential therapeutic value, Myriad said, and are the first demonstration of the technology's capability.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.